Agilis Biotherapeutics - Ownership and Business Overview

Life ScienceCompany

Agilis Biotherapeutics Ownership

Who owns Agilis Biotherapeutics?

Agilis Biotherapeutics is owned by PTC Therapeutics. It was acquired on July 19, 2018.

Agilis Biotherapeutics Business Overview

Where is Agilis Biotherapeutics headquartered?

Agilis Biotherapeutics is headquartered in Cambridge, Massachusetts.

What sector is Agilis Biotherapeutics in?

Agilis Biotherapeutics is a life science company.

When was Agilis Biotherapeutics founded?

Agilis Biotherapeutics was founded in 2013.

Life Science M&A Summary in 2018

Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2018. The largest life science acquisition in 2018 was Shire - which was acquired by Takeda Pharmaceutical for $67.7B.

Join Mergr to view all 246 acquisitions of life science companies in 2018, including 44 acquisitions by private equity firms, and 202 by strategics.

Agilis Biotherapeutics, Inc.

245 First Street Kendall Square, Suite 1800,
Cambridge, Massachusetts 02142
United States,
(214) 706-4340
www.agilisbio.com

Agilis Biotherapeutics, Inc. is a biotechnology company advancing an innovative gene therapy platform for rare monogenic diseases that affect the central nervous system (CNS). Agilis Biotherapeutics was founded in 2013 and is based in Cambridge, Massachusetts.


 Subscribe to unlock this and 207,814
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 200K M&A Transactions
  • 203K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.